Oruka Therapeutics Inc ORKA

US Biotechnology

$84.46 ▼ -1.20% ($-1.03)

Open $86.49

Prev Close $85.49

Day Range $84.00 – $86.49

52W Range $14.89 – $115.52

Market Cap $5.59B

Beta -0.39

EPS (TTM) $-2.46

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2000-07-21
Shares Out.	60,310,000
Website	orukatx.com/ ↗
Phone	13026587581
Employees	68
Revenue	$0
Gross Profit	$0
Net Income	-$41.2M
Free Cash Flow	-$101.2M
Total Assets	$1.14B
Total Liabilities	$24.8M
Equity	$1.11B

About Oruka Therapeutics Inc

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Oruka Therapeutics Inc is a publicly traded company under the ticker symbol ORKA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.